Gefitinib therapy for non-small cell lung cancer

Current Treatment Options in Oncology

Volumn 6, Issue 1, 2005, Pages 75-81

  Birnbaum, Ariel ^b   Ready, Neal ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; OXYGEN; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE; RADIOSENSITIZING AGENT; STEROID;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RISK; CELL LINE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DATA ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING SITE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG SAFETY; FEASIBILITY STUDY; FOLLOW UP; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS CELL CARCINOMA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; NAUSEA; PALLIATIVE THERAPY; RADIATION DOSE; RASH; REVIEW; RISK FACTOR; SURVIVAL; SURVIVAL RATE;

EID: 13544257464     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-005-0015-0     Document Type: Review

References (25)

1. Raben D, Helfrich B, Bunn P: Targeted therapies for non-small cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys 2004, 27-38.
2. Arteaga CL: Erb-B-targeted therapeutic approaches in human cancer. Exp Cell Res 2003, 122-130.
3. Bailey LR, Kris MA, Wolf M, et al.: Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (Iressa, ZD1839) monotherapy for pretreated advanced non-small cell lung cancer (IDEAL 1 & 2). Proc Am Assoc Can Res 2003, 1362.
4. Baselga J, Rischin D, Ranson M, et al.: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid-tumor types. J Clin Oncol 2002, 4292-4302.
5. Ochs J, Grous JJ, Warner KL: Final survey and safety results for 21,064 non-small cell lung cancer (NSCLC) who received compassionate use gefitinib in a US expanded access program (EAP). Proc Am Soc Clin Oncol 2004, 631s.
6. Fukouka M, Yano S, Giaccone G, et al.: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003, 21:2237-2246.
7. Kris MG, Natale RB, Herbst RS, et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 2149-2158.
8. Kane MA, Cohen E, List M, et al.: Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2004, 509s.
9. Cohen EEW, Stenson K, Gustin DM, et al.: A phase II study of 250 ing gefitinib (ZD1839) Monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2003, 502s.
10. Shepherd FA, Pereira L Ciuleanu TE, et al.: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Oncol 2004, 622s.
11. Miller V, Kris MG, Shah N, et al.: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer. J Clin Oncol 2004, 1103-1109.
12. West H, Franklin WA, Gumerlock PH, et al.: Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC) South West Oncology Group (SWOG) Study S0126, [abstract 7014]. Proc Am Soc Clin Oncol 2004, 620s.
13. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004, 2129-2139.
14. Paez JG, Janne PA, Lee JL, et al.: Epidermal growth factor receptor mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 1497-1500.
15. Hirsh FR, Franklin WA, Witta SE, et al.: Defining gefitinib sensitivity/resistance in non-small cell lung cancer (NSCLC) cell lines by affymetrix gene arrays. Proc Am Soc Clin Oncol 2004, 623s.
16. Strauss GM, Herndon J, Maddaus MA, et al.: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. Proc Am Soc Clin Oncol 2004, 621s.
17. Winton TL, Livingston R, Johnson D, et al.: A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non-small cell lung cancer (NSCLC) Intergroup JBR10. Proc Am Clin Oncol 2004, 621s.
18. Giaccone G, Herbst RS, Manegold C, et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 778-784.
19. Herbst RS, Giaccone G, Schiller JH, et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 2. J Clin Oncol 2004, 785-794.
20. Ready N, Herndon J, Vokes E, et al.: Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial. Proc Am Soc Clin Oncol 2004, 635s.
21. Rischin D, Burmeister B, Mitchell P, et al.: Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer. Proc Am Soc Clin Oncol 2004, 635s.
22. Inoue A, Saijo Y, Maemondo M, et al.: Severe acute interstitial pneumonia and gefitinib. Lancet 2003, 137-139.
23. Hotta K, Harita S, Bessho A, et al.: Interstitial lung disease (ILD) during gefitinib treatment in Japanese patients with non-small cell lung cancer (NSCLC) [abstract 7063]. Proc Am Soc Clin Oncol 2004, 632s.
24. Seto T and Yamamoto N: Interstitial lung disease (ILD) induced by gefitinib in patients with non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group [abstract 7064]. Proc Am Soc Clin Oncol 2004, 632s.
25. Gefitinib versus best supportive care (BSC) randomized evaluation of effect on pulmonary symptom endpoint (IBREESE) trial 710. Available at http://hcp.iressa.com/article/504595.aspx. Accessed October 1, 2004.